Olaparib plus bevacizumab as first-line maintenance in ovarian cancer

Researchers evaluated olaparib as a maintenance therapy in women undergoing standard first-line treatment with bevacizumab for newly diagnosed ovarian cancer. Participants in the multinational PAOLA-1 clinical trial had advanced disease and were eligible for enrollment whether they had a BRCA mutation or not.

Researchers evaluated olaparib as a maintenance therapy in women undergoing standard first-line treatment with bevacizumab for newly diagnosed ovarian cancer. Participants in the multinational PAOLA-1 clinical trial had advanced disease and were eligible for enrollment whether they had a BRCA mutation or not. Previous research has demonstrated the study intervention as clinically beneficially in the patient population who have the mutation; however, investigators wondered if the approach might also benefit women without it. All 806 trial patients received bevacizumab, with 537 randomly assigned to also take twice-daily oral olaparib and 269 allocated to placebo. The primary outcome was the time from randomization until disease progression or death. At median followup of 22.9 months, median progression-free survival was 22.1 months with bevacizumab plus olaparib vs. 16.6 months for the control patients. Investigators found the benefit to be substantial for patients with homologous-recombination deficiency-positive tumors, even in the absence of a BRCA mutation.